• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Pyxis Oncology Inc.

    4/30/26 7:40:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PYXS alert in real time by email
    DEFA14A 1 2026proxy_defa14a.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

    SCHEDULE 14A

    (Rule 14a-101)

    INFORMATION REQUIRED IN PROXY STATEMENT

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    Filed by the Registrant ☒

     

     

    Filed by a Party other than the Registrant  ☐

    Check the appropriate box:

    5 ☐

     

     

    Preliminary Proxy Statement

     ☐

     

     

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

     

     

    Definitive Proxy Statement

     ☒

     

     

    Definitive Additional Materials

     ☐

     

     

    Soliciting Material under § 240.14a-12

     

    PYXIS ONCOLOGY, INC.

    (Name of Registrant as Specified in its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒

     

     

    No fee required.

     ☐

     

     

    Fee paid previously with preliminary materials.

     ☐

     

     

    Fee computed on table in exhibit required per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     


    img53096847_0.jpg


    PYXIS ONCOLOGY P.O. Box 8016, CARY, NC 27512-9903 YOUR VOTE MATTERS! Scan QR for digital voting Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 11, 2024 For stockholders of record as of April 18, 2024 To order paper materials, use one of the following methods. INTERNET: www.investorelections.com/ Call 1-866-648-8133 paper@investorelections.com * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Pyxis Oncology, Inc. Annual Meeting of Stockholders Tuesday, June 11, 2024 10:00 AM, Eastern Time Annual Meeting to be held live via the internet - please visit at www.proxydocs.com/PYXS for more details. You must register to attend the meeting online and/or participate at www.proxydocs.com/PYXS For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/PYXS To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 31, 2024. SEE REVERSE FOR FULL AGENDA Copyright © 2024 BetaNXT, Inc. or its affiliates. All Rights Reserved

     

    img53096847_1.jpg

    THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1 AND 2 Pyxis Oncology, Inc. Annual Meeting of Stockholders 1. The election of one Class I director and three Class III directors named in the proxy statement 1.01 Santhosh Palani, Ph.D., CFA 1.02 John Flavin 1.03 Lara Sullivan,M.D. 1.04 Jakob Dupont,M.D. 2. The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December31, 2024 NOTE: The transaction of such other business as may properly come before the meeting, or any adjournment or postponement thereof.


    Get the next $PYXS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PYXS

    DatePrice TargetRatingAnalyst
    5/5/2026$6.00Outperform
    Wedbush
    11/3/2025$9.00Buy
    Stifel
    9/4/2025$5.00Buy
    Guggenheim
    11/21/2024Outperform → Mkt Perform
    William Blair
    11/8/2024$13.00Overweight
    Stephens
    8/8/2024$10.00Buy
    Stifel
    5/7/2024$10.00Buy
    Jefferies
    2/9/2024$8.00Buy
    BTIG Research
    More analyst ratings

    $PYXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO & COO Connealy Pamela Ann bought $174,364 worth of shares (88,850 units at $1.96) (SEC Form 4)

    4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

    11/27/24 5:09:59 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connealy Pamela Ann bought $14,960 worth of shares (8,000 units at $1.87), increasing direct ownership by 0.99% to 818,532 units (SEC Form 4)

    4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

    9/28/23 4:32:03 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wadhane Jitendra bought $4,675 worth of shares (2,500 units at $1.87), increasing direct ownership by 1% to 226,937 units (SEC Form 4)

    4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

    9/27/23 6:37:45 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYXS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

    Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) on track for mid-year 2026; update to include analyses focused on patients treated at or below a dose cap Completed target enrollment in Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC in the first quarter of 2026 Updated data from MICVO Phase 1/2 dose escalation study in combination with pembrolizumab in 1L R/M HNSCC on track for the second half of 2026 Presented new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2026 that support the clinical development of MICVO as both a monotherapy

    5/14/26 7:00:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology to Participate in Upcoming Investor Conferences

    BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcoming investor conferences: RBC Capital Markets Global Healthcare Conference in New York, NY on Tuesday, May 19, 2026, fireside chat at 2:35 p.m. ET; andStifel Virtual Oncology Forum on Wednesday, May 20, 2026, fireside chat at 3:30 p.m. ET; andJefferies Global Healthcare Conference in New York, NY on Thursday, June 4, 2026, fireside chat at 7:35 a.m. ET. Live webcasts and replays of the fireside chats will be available on the Events & Presentations

    5/13/26 7:30:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer

    BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the appointment of Nelson Azoulay as Chief Business Officer. Mr. Azoulay joins Pyxis Oncology with more than 15 years of experience in corporate strategy, business development, and value-creating transactions across the biopharma industry, including deep antibody-drug conjugate (ADC) experience. In his role, he will lead corporate development strategy and pursue strategic opportunities to advance MICVO, the Company's lead clinical asset. "We're excited to welcome Nelson to Pyxis Oncology," said Tom Ci

    5/7/26 4:05:00 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Dupont Jakob

    4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

    3/25/26 5:18:44 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Wadhane Jitendra

    4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

    3/25/26 5:17:26 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Flavin John L

    4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

    3/25/26 5:10:59 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYXS
    SEC Filings

    View All

    SEC Form 10-Q filed by Pyxis Oncology Inc.

    10-Q - Pyxis Oncology, Inc. (0001782223) (Filer)

    5/14/26 7:56:16 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Pyxis Oncology, Inc. (0001782223) (Filer)

    5/14/26 7:36:49 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Pyxis Oncology Inc.

    DEFA14A - Pyxis Oncology, Inc. (0001782223) (Filer)

    4/30/26 7:40:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on Pyxis Oncology with a new price target

    Wedbush initiated coverage of Pyxis Oncology with a rating of Outperform and set a new price target of $6.00

    5/5/26 7:44:12 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel resumed coverage on Pyxis Oncology with a new price target

    Stifel resumed coverage of Pyxis Oncology with a rating of Buy and set a new price target of $9.00

    11/3/25 9:08:29 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Pyxis Oncology with a new price target

    Guggenheim initiated coverage of Pyxis Oncology with a rating of Buy and set a new price target of $5.00

    9/4/25 9:07:21 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYXS
    Leadership Updates

    Live Leadership Updates

    View All

    Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

    Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) on track for mid-year 2026; update to include analyses focused on patients treated at or below a dose cap Completed target enrollment in Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC in the first quarter of 2026 Updated data from MICVO Phase 1/2 dose escalation study in combination with pembrolizumab in 1L R/M HNSCC on track for the second half of 2026 Presented new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2026 that support the clinical development of MICVO as both a monotherapy

    5/14/26 7:00:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer

    BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the appointment of Nelson Azoulay as Chief Business Officer. Mr. Azoulay joins Pyxis Oncology with more than 15 years of experience in corporate strategy, business development, and value-creating transactions across the biopharma industry, including deep antibody-drug conjugate (ADC) experience. In his role, he will lead corporate development strategy and pursue strategic opportunities to advance MICVO, the Company's lead clinical asset. "We're excited to welcome Nelson to Pyxis Oncology," said Tom Ci

    5/7/26 4:05:00 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quarter of 2026 Updated data from MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track for mid-year 2026; to include patients treated with modified weight-based dosing and patients treated with total body weight dosing Updated data from MICVO Phase 1/2 dose escalation study in combination with KEYTRUDA® in 1L/2L+ R/M HNSCC on track for the second half of 2026 Announced appointment of Thomas Civik as Interim Chief Executive Officer Expected cash runway into the fourth quarter of 2026 BOSTO

    3/23/26 7:00:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYXS
    Financials

    Live finance-specific insights

    View All

    Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

    46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in combination with KEYTRUDA® (pembrolizumab) in 1L/2L+ R/M HNSCC at 3.6 mg/kg and 4.4 mg/kgUpdated data from ongoing Phase 1 monotherapy study in 2L+ R/M HNSCC expected mid-2026; updated data from ongoing Phase 1/2 study evaluating MICVO in combination with KEYTRUDA®, including in 1L/2L+ R/M HNSCC and other tumor types, expected 2H26 Company to host webcast and conference call today at 8:30 a.m. ET BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage comp

    12/18/25 7:00:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024

    - Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and in-person event in New York City on Wednesday, November 20, 2024, at 4:30 p.m. ET - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. The Company ended the third quarter of 20

    11/12/24 7:30:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

    - Preliminary data from the Phase 1 trial of PYX-201 remains on track to be announced in the fall of 2024 - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. The Company ended the second quarter of 2024 with $157.2 million in cash, cash equivalents, restricted cash and short-term investments, which is expected

    8/14/24 4:05:00 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Pyxis Oncology Inc.

    SC 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)

    11/12/24 11:53:51 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Pyxis Oncology Inc.

    SC 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)

    11/6/24 4:36:24 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Pyxis Oncology Inc. (Amendment)

    SC 13D/A - Pyxis Oncology, Inc. (0001782223) (Subject)

    4/3/24 5:10:59 PM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care